Amanda McConnell-Mack, DO
Neurology · Gallipolis, OHNPI 1740424076
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 505 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 505 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Biogen$805
- Jazz Pharmaceuticals Inc.$603
- UCB, Inc.$455
- SK Life Science, Inc.$425
- MDD US Operations, LLC$394
- plus $5K from 54 others
Across 1 payment — averaging $2193.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$2K
What the payments were for
- Speaking & faculty fees$1051%
- Food & beverage$8,27595%
- Education$3674%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GOCOVRI$172
How this compares
$8,747 in reported general payments places this provider in the 75th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 32 | $272,868 |
| XywavSodium,calcium,mag,pot Oxybate | 11 | $187,333 |
| NuplazidPimavanserin Tartrate | 25 | $124,865 |
| AustedoDeutetrabenazine | 13 | $78,490 |
| XcopriCenobamate | 44 | $60,948 |
| Nurtec OdtRimegepant Sulfate | 28 | $44,532 |
| ValtocoDiazepam | 31 | $43,947 |
| QuliptaAtogepant | 35 | $42,881 |
| VimpatLacosamide | 17 | $38,919 |
| RexultiBrexpiprazole | 22 | $37,327 |
| Teriflunomide | 27 | $32,026 |
| BriviactBrivaracetam | 21 | $28,787 |
| Emgality PenGalcanezumab-Gnlm | 37 | $28,595 |
| Aimovig AutoinjectorErenumab-Aooe | 32 | $28,415 |
| Oxtellar XrOxcarbazepine | 28 | $26,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $74 | $124,86525 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $166 | $78,49013 claims |
| UCB, Inc.Vimpat, Briviact, Nayzilam | $455 | $76,83652 claims |
| SK Life Science, Inc.Xcopri | $425 | $60,94844 claims |
| AbbVieQulipta, Ubrelvy | $1,427 | $57,39046 claims |
| PfizerNurtec Odt, Dilantin | $97 | $52,73846 claims |
| Neurelis, Inc.Valtoco | $182 | $43,94731 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $88 | $37,32722 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $15 | $26,36528 claims |
| Lilly USA, LLCReyvow | $360 | $11,47114 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $65 | $10,098130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 702 neurology providers in Ohio.
Other neurology in Gallipolis
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
- Lawrence GoldstickDayton$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.